STOCK TITAN
  1. Home
  2. News
  3. EXAS

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.

In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.

The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.

  • Headquartered in Madison, Wisconsin
  • Specializes in cancer screening and diagnostic tests
  • Flagship product: Cologuard, a noninvasive colorectal cancer screening test
  • Precision oncology products: Oncotype DX and OncoExTra
  • Active development of liquid biopsy tests
  • Exclusive intellectual property rights protecting screening technology

For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.

News

Exact Sciences Announces Second-Quarter 2023 Results

Rhea-AI Summary
Exact Sciences Corp. reports record results for the second quarter of 2023, with total revenue of $622 million, an increase of 19%. The company also generated positive free cash flow of $66 million and raised its full-year revenue and adjusted EBITDA guidance. Exact Sciences anticipates revenue of $2.441-$2.466 billion for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.73%
Tags
earnings
-
News

Exact Sciences schedules second quarter 2023 earnings call

Rhea-AI Summary
Exact Sciences Corp. plans to release its second quarter 2023 financial results on August 1, 2023. The company will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
earnings
-
News

Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
News

Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening

Rhea-AI Summary
Exact Sciences Corp. announced positive top-line results from the pivotal BLUE-C study, showing that next-generation Cologuard met all study endpoints and improved every top-line metric. The results include a 30% lower false positive rate compared to the FDA registrational trial for Cologuard. The study reflects the racial and ethnic diversity of the U.S. with 20,000 participants. The company plans to complete FDA submission for next-generation Cologuard by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
none
-
News

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATION™

Rhea-AI Summary
Exact Sciences Corp. has been certified as a 2023 Great Place To Work® for the fifth consecutive year. This year, 82% of Exact Sciences employees said that it is a Great Place To Work, surpassing the average U.S. company by 25 points. The certification is based on a confidential survey open to U.S.-based employees, evaluating the company's work environment, culture, and leadership. Great Place To Work is known for delivering market-leading revenue, employee retention, and increased innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
News

Exact Sciences to participate in June investor conferences

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
conferences
News

Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023

Rhea-AI Summary
Exact Sciences to present new data confirming approach to multi-cancer early detection, real-world outcomes using Oncotype DX Breast Recurrence Score, and modeling comparisons between Cologuard and blood-based tests for colorectal cancer at ASCO Annual Meeting 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
News

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
News

Exact Sciences Announces First Quarter 2023 Results

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.89%
Tags
earnings
News

Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none

FAQ

What is the current stock price of Exact Sciences (EXAS)?

The current stock price of Exact Sciences (EXAS) is $59.4 as of December 20, 2024.

What is the market cap of Exact Sciences (EXAS)?

The market cap of Exact Sciences (EXAS) is approximately 10.5B.

What is Exact Sciences Corp's main business?

Exact Sciences Corp specializes in molecular diagnostics, focusing on innovative cancer screening and diagnostic test products.

What is Cologuard?

Cologuard is a noninvasive stool-based DNA test designed to screen for colorectal cancer, integrated into major colorectal cancer screening guidelines.

Where is Exact Sciences Corp headquartered?

The company is headquartered in Madison, Wisconsin.

What are Oncotype DX and OncoExTra?

Oncotype DX is a suite of tissue-based genomic tests for cancer recurrence risk and chemotherapy benefit; OncoExTra is a liquid biopsy for comprehensive genomic profiling.

Is Exact Sciences developing any new tests?

Yes, the company is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

What is the significance of Exact Sciences' intellectual property?

Exact Sciences has exclusive intellectual property rights protecting its noninvasive molecular screening technology, reinforcing its market leadership.

Are Exact Sciences' products used internationally?

Yes, Exact Sciences provides cancer screening and diagnostic test products both in the United States and internationally.

How does Cologuard work?

Cologuard works by analyzing stool samples for DNA markers and blood that could indicate the presence of colorectal cancer or precancerous lesions.

What is the purpose of Oncotype DX tests?

Oncotype DX tests aim to estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy in breast and colon cancer patients.

Where can more information about Cologuard be found?

More information about Cologuard can be found at cologuardtest.com.

Stock EXAS logo
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

#828 Ranked by Market Cap
N/A Ranked by Dividends

EXAS Stock Data

10.55B
182.40M
1.01%
101.74%
7.48%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
MADISON